Suzhou Hybiome Biomedical Engineering Co. Ltd.

https://www.hybiome.com

Suzhou Hybiome Biomedical Engineering Co.Ltd has been founded in 2009 and is based in Suzhou (China), Hybiome is specialized in automated immunoassay tests. The company develops, manufactures and markets a complete range of diagnostic solutions (reagents, instruments and software) cleared by the China Food and Drug Administration (CFDA). Hybiome markets two automated, mid-throughput immunoassay systems (AE-180 and AE-240) using the latest generation CLIA1 technology and featuring a menu of nearly 80 parameters. Hybiome also recently received CFDA clearance for the AE-120 system, to further increase access to its menu of assays. Hybiome’s installed base has about 1,000 active instruments that are used primarily in medium-size hospitals (100 to 500 beds), known as Grade 2 facilities. In China, the immunoassay market represents around €2 billion and reports growth of about 20-25%. It has witnessed the increasingly important role of local suppliers, especially within the Grade 2 hospital segment. Hybiome employs around 300 people, including close to 80 employees in R&D. The company has both manufacturing facilities and research laboratories, with plans for expansion within the Suzhou Industrial-Medical Park. It expects to exceed 20 million euros in sales in 2018, a sharp increase over 2017. *

	Start	2009-01-01 established
	Group	Mérieux (Group)
	Industry	molecular diagnostics
	Person	Dong, Jianhua (Hybiome (CN) 2009– Founder + Chairman)
	Person 2	Boulud, Pierre (Mérieux 202310 CEO of bioMèrieux joined 11/16 before Ipsen + Boston Consulting + Bossard Consultants)

	Region	Suzhou
	Country	China
	Street	Jinfeng Road Block 4, No. 8
	City	Suzhou
	Tel	+86-512-66895311
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2018-11-09)
	Currency	EUR
	Annual sales	20,000,000 (sales, annual, expected (2018) 2018-12-31)

		* Document for »About Section«:

		Record changed: 2024-08-24